中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
30期
10-11
,共2页
万金华%张丽华%张学钰%范海银%付洪帆%易向军
萬金華%張麗華%張學鈺%範海銀%付洪帆%易嚮軍
만금화%장려화%장학옥%범해은%부홍범%역향군
局限性非小细胞肺癌%吉非替尼%复发率%转移率
跼限性非小細胞肺癌%吉非替尼%複髮率%轉移率
국한성비소세포폐암%길비체니%복발솔%전이솔
Localized NSCLC%Gefitinib%Recurrence rate%Transport rate
目的:探讨吉非替尼术前辅助化疗对局限性非小细胞肺癌(NSCLC)患者的作用。方法:将96例局限性NSCLC患者分为观察组(52例)和对照组(44例),两组患者均给予择期手术治疗,观察组在术前给予250 mg/d吉非替尼辅助化疗,观察两组患者治疗疗效。结果:观察组术后局部复发率为3.85%(2/52)、远处转移率1.92%(1/52),明显低于对照组的11.36%(5/44)和6.82%(3/44),差异具有统计学意义(P<0.05);观察组患者术后1年生活质量优于对照组(P<0.05);两组患者1年生存率及术后并发症发生率比较无统计学意义(P>0.05)。结论:在NSCLC术前给予吉非替尼辅助化疗,可在降低复发及转移率的同时提高患者术后生活质量,对减轻患者痛苦、改善患者预后有积极意义。
目的:探討吉非替尼術前輔助化療對跼限性非小細胞肺癌(NSCLC)患者的作用。方法:將96例跼限性NSCLC患者分為觀察組(52例)和對照組(44例),兩組患者均給予擇期手術治療,觀察組在術前給予250 mg/d吉非替尼輔助化療,觀察兩組患者治療療效。結果:觀察組術後跼部複髮率為3.85%(2/52)、遠處轉移率1.92%(1/52),明顯低于對照組的11.36%(5/44)和6.82%(3/44),差異具有統計學意義(P<0.05);觀察組患者術後1年生活質量優于對照組(P<0.05);兩組患者1年生存率及術後併髮癥髮生率比較無統計學意義(P>0.05)。結論:在NSCLC術前給予吉非替尼輔助化療,可在降低複髮及轉移率的同時提高患者術後生活質量,對減輕患者痛苦、改善患者預後有積極意義。
목적:탐토길비체니술전보조화료대국한성비소세포폐암(NSCLC)환자적작용。방법:장96례국한성NSCLC환자분위관찰조(52례)화대조조(44례),량조환자균급여택기수술치료,관찰조재술전급여250 mg/d길비체니보조화료,관찰량조환자치료료효。결과:관찰조술후국부복발솔위3.85%(2/52)、원처전이솔1.92%(1/52),명현저우대조조적11.36%(5/44)화6.82%(3/44),차이구유통계학의의(P<0.05);관찰조환자술후1년생활질량우우대조조(P<0.05);량조환자1년생존솔급술후병발증발생솔비교무통계학의의(P>0.05)。결론:재NSCLC술전급여길비체니보조화료,가재강저복발급전이솔적동시제고환자술후생활질량,대감경환자통고、개선환자예후유적겁의의。
Objective:To investigate the effects of the preoperative adjuvant chemotherapy of gefitinib on the treatment of localized NSCLC. Method:96 cases localized NSCLC were divided into the observation group(with 52 cases)and the control group(with 44 cases). Both groups were treated with selective operation. The observation group was treated with preoperative adjuvant chemotherapy of 250 mg/d gefitinib. Observations were carried out about the efficacy of both groups. Result:The post-operative local recurrence rate and the distant metastasis rate of the observation group were respectively 3.85%(2/52)and 1.92%(1/52),significantly lower than 11.36%(5/44)and 6.82%(3/44)of the control group(P<0.05). The life quality of the observation group one year after the operation was better than that of the control group(P<0.05). There was no statistic significance in the comparison of both groups’ one-year production rate and occurrence rate of post-operative complications(P>0.05). Conclusion:Applying preoperative adjuvant chemotherapy of gefitinib on the treatment of localized NSCLC can reduce the recurrence rate and the transport rate and improve patients’ postoperative life quality,as well as imposing positive effects on alleviating patients’ pain and improve their prognosis.